Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3145–3168 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: Pleural Effusion, Single-ventricle
Interventions: Vasopressin, Normal Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Months to 7 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more

Conditions: Down Syndrome
Interventions: Hip Helpers home program; Other
Lead sponsor: University of St. Augustine for Health Sciences; Other
Eligibility: 3 Months to 15 Months
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: San Marcos, California • Saint Augustine, Florida • Austin, Texas

Conditions: Muscular Dystrophy, Duchenne
Interventions: Magnetic Resonance Imaging (MRI), Pulmonary Function Testing (PFT), Metabolic Exercise Testing using stationary bicycle, Echocardiogram; Other
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 15 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Atopic Dermatitis
Interventions: Nemolizumab, CYP 450 Substrates; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: North Hollywood, California • Hallandale, Florida • Miami, Florida + 2 more

Conditions: Neurofibromatosis Type 1, Plexiform Neurofibroma
Interventions: Binimetinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more

Conditions: Charcot Marie Tooth Disease (CMT), Hereditary Sensory and Motor Neuropathy, Nerve Compression Syndromes, Tooth Diseases, Congenital Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Inherited Mitochondrial Disease
Interventions: Vatiquinone; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Not listed
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: La Jolla, California • Stanford, California • New Haven, Connecticut + 10 more

Conditions: Congenital Hyperinsulinism
Interventions: Glucagon, Placebo; Drug · Other
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: Up to 12 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • St Louis, Missouri + 2 more

Conditions: Familial Adenomatous Polyposis (FAP)
Interventions: eRapa (encapsulated rapamycin), Placebo; Drug
Lead sponsor: Rapamycin Holdings Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 18
States / cities: Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Familial Adenomatous Polyposis
Interventions: Celecoxib, Colonoscopy Biopsy; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Anemia
Interventions: Amicus Red Cell Exchange in SCD patients; Device
Lead sponsor: Fenwal, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Phoenix, Arizona • Detroit, Michigan • St Louis, Missouri + 3 more

Conditions: Cystic Fibrosis
Interventions: epithelial cells and blood lymphocyte extraction; Procedure
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 15 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Congenital Adrenal Hyperplasia, Hyperplasia, Adrenal Hyperplasia, Congenital Disorders, Adrenocortical Hyperfunction, Disorders of Sex Development, Urogenital Abnormalities, Genetic Diseases, Inborn, Steroid Metabolic Diseases, Inborn, Adrenal Gland Disease, Hydrocortisone
Interventions: Subcutaneous hydrocortisone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 4 Years to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Developmental Disability, Autism Spectrum Disorder, Down Syndrome, Cerebral Palsy
Interventions: Zumba High Tempo, Zumba Low Tempo; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: DSD, Hypospadias
Interventions: Narrative Medicine Journaling Intervention; Behavioral
Lead sponsor: Sarah Schlegel; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis, Ventilatory Defect
Interventions: 19F MRI; Combination Product
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Thyroid Eye Disease
Interventions: AMG 732, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more

Conditions: Immune System Diseases
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions: 17 beta estradiol; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 10 Years to 16 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Gout
Interventions: Pharmacist-Led Intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 1,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Birmingham, Alabama • Pasadena, California

Conditions: Monochorionic Diamniotic Placenta, Monochorial Monoamniotic Placenta, Twin; Complicating Pregnancy, Twin to Twin Transfusion Syndrome, Twin Reversal Arterial Perfusion Syndrome
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: Not listed
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Angelman Syndrome, Nervous System Diseases
Interventions: Betaine, Creatine, Metafolin, Vitamin B12; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 1 Day to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Greenwood, South Carolina + 1 more

Search by objective public record fields.

Use of Vasopressin Following the Fontan Operation

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Impact of an Orthotic Garment on Gross Motor Skills for Infants With Down Syndrome

Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients

A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers

Evaluation of the AMICUS RBCx System in Sickle Cell Patients

Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

The Effects of Virtual Zumba® in Individuals With Developmental Disabilities

Breaking Silence Through Story: A Narrative Medicine Intervention for Parents of Children With Urogenital Conditions

Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Developing Newborn Screening for Infants With Primary Immunodeficiency

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

Virtual Gout Clinic

Database of Monochorionic Pregnancies

Dietary Supplements for the Treatment of Angelman Syndrome